Equillium Inc
USUSDEquillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O Podjetju
- Spletna Stran
- equilliumbio.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- LA JOLLA, United States
- Izvršni Direktor
- Bruce Steel
- Zaposleni
- 14
- Delnice v Obtoku
- 63.41 mio. na dan 2026-08-07
- Prosto Prenosljive Delnice
- 36.97 mio.
- Tržna Kapitalizacija
- 89.41 mio. USD
- Notranje Osebe
- 16%
- Institucionalni Vlagatelji
- 65.76%
- Panoga (SIC)
- Pharmaceutical Preparations
- FCF
- −20.1 mio. USD
- Dolg
- 7.64 mio. USDneto denar
- Dobiček in FCF — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Novice Ta Teden
Sporočila za javnost s spletne strani za vlagatelje podjetja, ki se dnevno posodabljajo. Povezave vodijo na spletno stran podjetja. Naslovi so v izvirnem jeziku, kot na spletni strani podjetja.
Največji Imetniki
| Imetnik | Delež | Delnice | Datum Poročila |
|---|---|---|---|
| Jupiter Topco LLC | 10.24% | 6.49 mio. | 2026-06-30 |
| Decheng Capital LLC | 7.01% | 4.45 mio. | 2026-06-30 |
| Affinity Asset Advisors,… | 6.47% | 4.1 mio. | 2026-06-30 |
| Adar1 Capital Management… | 5.93% | 3.76 mio. | 2026-06-30 |
| Aberdeen Group plc | 5.73% | 3.63 mio. | 2026-06-30 |
| abrdn Life Sciences Inve… | 5.73% | 3.63 mio. | 2026-06-30 |
| Woodline Partners LP | 5.52% | 3.5 mio. | 2026-06-30 |
| RA Capital Management, L… | 4.88% | 3.1 mio. | 2026-06-30 |
| Stempoint Capital LP | 3.18% | 2.02 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 2.87% | 1.82 mio. | 2026-06-30 |
| Eversept Partners, LP | 2.4% | 1.52 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.21% | 1.4 mio. | 2026-06-30 |
| CONNELLY STEPHEN (Presid… | ≈1.2% | 762 025 | 2026-06-05 |
| VANGUARD INDEX FUNDS-Van… | 0.54% | 344 489 | 2026-06-30 |
| Fidelity Concord Street… | 0.26% | 162 851 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.24% | 153 076 | 2026-08-31 |
| American Century ETF Tru… | 0.12% | 75 411 | 2026-08-31 |
| ZEDELMAYER CHRISTINE (Ch… | ≈0.1% | 62 586 | 2026-06-05 |
| Fidelity Concord Street… | 0.09% | 54 677 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 47 465 | 2026-07-31 |
| Invesco Exch-Trd Fd. TRT… | 0.06% | 38 516 | 2026-08-31 |
| Fidelity Concord Street… | 0.06% | 36 683 | 2026-07-31 |
| TOM PENNY (Officer) | — | 0 | 2026-05-28 |
| KEYES JASON A (Chief Fin… | — | — | 2025-01-23 |
